权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular Pathology and Genomics Core

分子病理学和基因组学核心

基本信息

批准号：
10673111
负责人：
JON C. ASTER
金额：
$ 27.24万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10673111
关键词：
Academic Medical Centers Address BCL2 gene BCL2L1 gene Biological Markers Boston CLIA certified Cancer Center Cells Cities Classification Clinical Collection Color Complement Consensus DNA Dana-Farber Cancer Institute Data Data Analyses Development Diagnosis Diagnostic Equipment Evaluation Formalin Functional disorder Genes Genetic Genomics Genotype Hematologic Neoplasms Hematopathology Histology Histopathology Hospitals Human IL2RA gene Immune Immune response Immunofluorescence Immunologic In Situ Institution International Knowledge Link Lymphoma MCL1 gene MDM2 gene Memorial Sloan-Kettering Cancer Center Modeling Mus Mutate Normal tissue morphology North Carolina Paraffin Embedding Pathologic Pathologist Pathology Periodicity Peripheral Primary Neoplasm Protocols documentation Research Research Personnel Resistance Resource Sharing Resources STAT5B gene Sampling Services Site Slide Stains System Systems Analysis T-Cell Lymphoma TP53 gene Testing Tissue Embedding Universities Woman cohort data analysis pipeline driver mutation experience genomic data imaging platform innovation liquid crystal polymer molecular pathology mouse model neoplastic cell novel novel therapeutics performance site programs reagent standard response success targeted exome sequencing therapeutic target tumor microenvironment web interface web site working group

项目摘要

PROJECT SUMMARY Core C provides access to specialized professional and technical pathology services and genomic services that are essential to the success of the Program. It does so by carrying out 3 overarching aims that support all three P01 Projects: 1) provide pathology expertise needed for classification of primary human PTCLs and PDX and murine PTCL models; 2) perform standard and novel in situ tests for biomarkers relevant to understanding PTCL pathophysiology and its response and resistance to novel therapies; and 3) perform targeted exome sequencing of a large cohort of well-characterized human PTCLs. The Core delivers these services at two performance sites, one in Boston led by Jon Aster, which will deliver services supporting Aims 1 and 2, and the second in North Carolina led by Sandeep Dave, which will deliver services supporting Aims 1 and 3. Delivery of Aim 1 services relies on the Core's co-leader, Dr. Jon Aster, who is a practicing academic hematopathologist with >25 years of experience with human and murine hematopathology, and is supplemented by additional expertise in Project 1 (John Chan) and access to the Hematologic Malignancies Research Consortium, which includes >25 institutions and has accrued over 1800 cases of T cell lymphomas, a majority with paired normal tissue. Aim 2 services will be provided in Boston include standard histology and immunohistology services and innovative, multiparametric immunofluorescence staining platforms, the Perkin- Elmer Vectra platform and CyCIF is an iterative imaging platform that allows for evaluation of >50 different markers on single FFPE slides. Aim 3 services are delivered at the North Carolina performance site by performing targeted exome sequencing on 410 genes that are frequently mutated in lymphoma, initially using DNA prepared from a cohort of 1833 PTCLs and paired normal tissue controls.

项目概要 Core C 提供专门的专业技术病理学服务和基因组服务这对于该计划的成功至关重要。它通过实现支持所有方面的 3 个总体目标来实现这一目标三个 P01 项目：1) 提供原发性人类 PTCL 和 PDX 分类所需的病理学专业知识和小鼠PTCL模型； 2) 对与理解相关的生物标志物进行标准和新颖的原位测试 PTCL病理生理学及其对新疗法的反应和耐药性； 3) 执行靶向外显子组对一大群特征明确的人类 PTCL 进行测序。核心以两种方式提供这些服务性能站点，其中一个位于波士顿，由 Jon Aster 领导，将提供支持目标 1 和 2 的服务，以及第二个位于北卡罗来纳州，由 Sandeep Dave 领导，将提供支持目标 1 和 3 的服务。 Aim 1 服务依赖于核心的联合领导者 Jon Aster 博士，他是一名执业学者具有超过 25 年人类和小鼠血液病理学经验的血液病理学家，辅以项目 1 (John Chan) 的额外专业知识和血液恶性肿瘤的机会研究联盟由超过 25 个机构组成，已收集了 1800 多例 T 细胞淋巴瘤病例，大多数与配对的正常组织。波士顿将提供目标 2 服务，包括标准组织学和免疫组织学服务和创新的多参数免疫荧光染色平台，Perkin- Elmer Vectra 平台和 CyCIF 是一个迭代成像平台，允许评估 > 50 种不同的单张 FFPE 载玻片上的标记。 Aim 3 服务由北卡罗来纳州表演场地提供对淋巴瘤中经常突变的 410 个基因进行靶向外显子组测序，最初使用 DNA 从 1833 个 PTCL 队列和配对的正常组织对照中制备。